U.S. markets closed
  • S&P Futures

    3,852.25
    +13.25 (+0.35%)
     
  • Dow Futures

    31,612.00
    +147.00 (+0.47%)
     
  • Nasdaq Futures

    12,662.75
    -1.00 (-0.01%)
     
  • Russell 2000 Futures

    2,210.60
    +20.90 (+0.95%)
     
  • Crude Oil

    67.52
    +1.43 (+2.16%)
     
  • Gold

    1,704.90
    +6.40 (+0.38%)
     
  • Silver

    25.48
    +0.19 (+0.76%)
     
  • EUR/USD

    1.1932
    +0.0007 (+0.06%)
     
  • 10-Yr Bond

    1.5540
    +0.0040 (+0.26%)
     
  • Vix

    24.66
    -3.91 (-13.69%)
     
  • GBP/USD

    1.3855
    +0.0027 (+0.20%)
     
  • USD/JPY

    108.3700
    -0.0120 (-0.01%)
     
  • BTC-USD

    51,481.67
    +2,359.68 (+4.80%)
     
  • CMC Crypto 200

    1,040.86
    +97.68 (+10.36%)
     
  • FTSE 100

    6,630.52
    -20.36 (-0.31%)
     
  • Nikkei 225

    29,205.11
    +340.79 (+1.18%)
     

Optinose to Present at the BMO 2020 Prescriptions for Success Healthcare Conference

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

YARDLEY, Pa., June 22, 2020 (GLOBE NEWSWIRE) -- Optinose (OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that Chief Executive Officer Peter Miller will present a company overview and business update at the BMO 2020 Prescriptions for Success Healthcare Conference on June 23, 2020, at 9:00 a.m. ET.

To listen to a webcast of the presentation live, please visit the Investors page of the Optinose website.

A replay of the webcast will be available for 30 days following the conclusion of the event.

About Optinose
Optinose is a global specialty pharmaceutical company focused on serving the needs of patients cared for by ear, nose and throat (ENT) and allergy specialists. To learn more, please visit www.optinose.com or follow us on Twitter and LinkedIn.

Optinose Investor Contact
Jonathan Neely
jonathan.neely@optinose.com
267.521.0531